文献速递泌尿男性生殖肿瘤

双相雄激素治疗使去势抵抗性前列腺癌对后续雄激素受体靶向治疗增敏

Bipolar androgen therapy sensitizes castration-resistant prostate cancer to subsequent androgen receptor ablative therapy.
PubMed 文献 · Eur J Cancer · 2020-12-29

这项单中心、开放标签、II期多队列试验的C队列纳入29例去势抵抗性前列腺癌(CRPC)患者,评估双相雄激素治疗(BAT)作为一线激素治疗的安全性和有效性。BAT治疗后4/29例(14%;95%CI 4-32%)达到PSA50缓解,转移性CRPC患者的中位影像学无进展生存期为8.5个月(95%CI 6.9-15.1)。BAT进展后,18例中17例(94%;95%CI 73-100%)对阿比特龙或恩扎卢胺达到PSA50缓解,15/18例(83%;95%CI 59-96%)达到PSA90缓解。

要点

  • BAT一线治疗CRPC的PSA50缓解率为14%(4/29;95%CI 4-32%)
  • 转移性CRPC患者BAT的中位影像学无进展生存期为8.5个月(95%CI 6.9-15.1)
  • BAT进展后阿比特龙或恩扎卢胺的PSA50缓解率为94%(17/18;95%CI 73-100%)

核心结论

  • BAT作为CRPC一线激素治疗耐受良好,并带来持续疾病稳定。
  • BAT进展后患者对第二代雄激素受体靶向治疗仍可获得良好缓解。

研究设计与样本

  • 单中心、开放标签、II期多队列试验(RE-sensitizing with Supraphysiologic Testosterone to Overcome REsistance研究)的C队列。
  • 29例CRPC患者接受一线激素治疗:睾酮环戊丙酸酯400 mg肌内注射每28天一次,同时联用促黄体生成素释放激素激动剂/拮抗剂。
  • 主要终点为BAT治疗的PSA50缓解率。

主要发现

  • BAT治疗后4/29例(14%;95%CI 4-32%)达到PSA50缓解。
  • 转移性CRPC患者BAT的中位影像学无进展生存期为8.5个月(95%CI 6.9-15.1)。
  • BAT进展后,18例中17例(94%;95%CI 73-100%)对阿比特龙或恩扎卢胺达到PSA50缓解。
  • BAT进展后,18例中15例(83%;95%CI 59-96%)对阿比特龙或恩扎卢胺达到PSA90缓解。

临床怎么用

  • BAT可作为CRPC一线激素治疗的耐受性良好选择,用于诱导疾病稳定。
  • BAT进展后序贯阿比特龙或恩扎卢胺可能提高PSA缓解率。

局限性

  • 单中心、开放标签、II期试验,样本量小(C队列29例)。
  • BAT一线治疗的PSA50缓解率较低(14%)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cyclical, high-dose testosterone administration, termed bipolar androgen therapy (BAT), can induce clinical responses and restore sensitivity to androgen signalling inhibition in patients with previously treated castration-resistant prostate cancer (PCa) (CRPC). This trial evaluated whether BAT is a safe and effective first-line hormonal therapy for patients with CRPC. PATIENTS AND METHODS: In cohort C of this single-centre, open-label, phase II, multi-cohort trial (RE-sensitizing with Supraphysiologic Testosterone to Overcome REsistance study), 29 patients with CRPC received first-line hormonal therapy with 400 mg of testosterone cypionate intramuscularly every 28 days concurrent with a luteinising hormone-releasing hormone agonist/antagonist. The primary end-point of the study was the PSA50 response rate to BAT treatment. RESULTS: After treatment with BAT, four of 29 patients (14%; 95% confidence interval [CI]: 4-32%) experienced a PSA50 response. The median radiographic progression-free survival to BAT was 8.5 months (95% CI: 6.9-15.1) for patients with metastatic CRPC. After progression on BAT, 17 of 18 patients (94%; 95% CI: 73-100%) achieved a PSA50 response and 15 of 18 patients (83%; 95% CI: 59-96) achieved a PSA90 response on abiraterone or enzalutamide. Twelve of 15 patients (80%; 95% CI: 52-96) with metastatic CRPC remain on abiraterone or enzalutamide with a median duration of follow-up of 11.2 months. CONCLUSION: As first-line hormonal treatment for CRPC, BAT was well tolerated and resulted in prolonged disease stabilisation. After progression on BAT, patients had favourable responses to second-generation androgen receptor-targeted therapy. TRIAL REGISTRATION: ClinicalTrials.gov NCT02090114.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Sena LA, Wang H, Lim ScM SJ, et al. Bipolar androgen therapy sensitizes castration-resistant prostate cancer to subsequent androgen receptor ablative therapy. Eur J Cancer. 2020. PMID: 33383350. doi:10.1016/j.ejca.2020.11.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。